1. Moser W, Smith D, Watkins A, Powers J, Moser B. X-linked adrenoleukodystrophy. In Scriver CR, Beaudet AL, Sly WS, Valle D, Eds. The Metabolic and Molecular Bases of Inherited Disease, 8th ed. New York: McGraw-Hill. 2001; 325-3301.
2. Shapiro E, Krivit W, Lockman L, Jambaque I, Peters C, Cowan M, Harris R, Blanche S, Bordigoni P, Loes D. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet 2000; 356(9231): 713-718.
3. Singh I, Pahan K, Khan M. Lovastatin and sodium phenylacetate normalize the levels of very long chain fatty acids in skin fibroblasts of X-adrenoleukodystrophy. FEBS Lett 1998; 426(3): 342-346.
4. Pai S, Khan M, Barbosa E, Key L, Craver R, Cure K, Betros R, Singh I. Lovastatin therapy for X-linked adrenoleukodystrophy: clinical and biochemical observations on 12 patients. Mol Gen Metab 2000; 69(4): 312-322.
5. Sarde O, Mosser J, Kioschis P. Genomic organization of the adrenoleukodistrophy gene. Genomics 1993; 22(1): 13-20.
6. Kobayashi T, Yamada T, Yasutake T. Adrenoleucodystrophy gene encodes 80 kDa membrane protein. Biochem Biophys Res Commun 1994; 201(2): 1029-1034.
7. Watkins A, Gould J, Smith A. Altered expression of ALDP in X-linked adrenoleukodystrophy. Am J Hum Genet 1995; 57(2):292-301.
8. Moser W, Moser B, Kawamura N. Adrenoleukodystrophy: elevated C26 fatty acid in cultured skin fibroblasts. Ann Neurol 1980; 7(6): 542-549.
9. Moser W, Moser B, Frayer K. Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids. Neurology 1981; 31(10): 1241-1246.
10. Whitcomb W, Linehan M, Wahl M, Knazek A. Monocytes stimulate cortisol production by cultured human adrenocortical cells. J Clin End Metab 1988; 66(2): 33-38.
11. Powers M, Liu Y, Moser A, Moser H. The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules and pathogenetic implications. J Neuropathol Exp Neurol 1992; 51(6): 630-643.
12. Moser W, Moser B, Smith D, Bergin A, Borel J, Shankroff J, Stine C, Merette C, Ott J, Krivit W, Shapiro E. Phenotypic variability:implications for therapy. J Inher Metab Dis 1992; 15(4): 645-664.
13. Powers M. Adreno-leukodystrophy (adreno-testiculo-leukomyelo-neuropathic-complex). Clin Neuropathol 1985; 4(5): 181-199.
14. Boles J, Craft A, Padgett A, Loria M, Rizzo B. Clinical variation in X-linked adrenoleukodystrophy: fatty acid and lipid metabolism in cultured fibroblasts. Biochem Med Metab Bio 1991; 45(1): 74-91.
15. Kok F, Neumann S, Sarde O. Mutational analysis of patients with X-linked adrenoleukodystrophy. Hum Mutat 1995; 6(2):104-115.
16. Moser H, Dubey P, Fatemi A. Progress in X-linked adrenoleukodystrophy. Curr Opin Neurol 2004; 17(3): 263-269.
17. Smith D, Sack G, Beaty T. A genetic basis for the multiple phenotypes of X-linked adrenoleukodystrophy. Am J Hum Genet 1991; 49(3): 165-168.
18. Maestri E, Beaty H. Predictions of a 2-locus model for disease heterogeneity: applications to adrenoleuleukodystrophy. Am J Hum Genet 1992; 44(5): 576-582.
1 Department of Pediatrics, Mother and Child Health Care Institute of Serbia, Belgrade, Serbia and Montenegro
2 Department of Gynecology, Mother and Child Health Care Institute of Serbia, Belgrade, Serbia and Montenegro
3 Institute of Pathological Phisyology, Medical Faculty Kragujevac, Kragujevac, Serbia
4 Institute of Pathological Phisyology, Medical Faculty Belgrade, Belgrade, Serbia
